Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($1.01), $0.08 worse than the analyst estimate of ($0.93). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $50 thousand.

2017 Financial Outlook

Revance reaffirmed its financial guidance provided in January 2017. Revance expects cash burn for 2017 to be in the range of $102 to $112 million. Revance expects 2017 GAAP operating expense to be in the range of $108 to $119 million, which when excluding depreciation of $1 to $2 million and estimated stock-based compensation of $13 to $15 million, results in projected 2017 non-GAAPoperating expense of $94 to $102 million. Revance anticipates 2017 GAAP research and development expense to be in the range of $75 to $83 million, which when excluding depreciation of $1 to $2 million and estimated stock-based compensation of $5 to $6 million, results in projected 2017 non-GAAP research and development expense of $69 to $75 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.